Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors

A method of inhibiting PDGFR and/or cFMS and/or cKIT in a mammal, comprising administering to said mammal a compound having the general formula I

• or a pharmaceutically acceptable salt thereof, wherein:
• R1 is hetAr1(CH2)m—, hetAr2CH2—, hetAr3CH2—, (3-6C cycloalkyl)-CH2—, hetCyc1CH2—, Ar1(CH2)n— or (N-1-3C alkyl)pyridinonyl-CH2—;
• hetAr1 is a 6-membered heteroaryl having 1-2 ring N atoms and optionally substituted with one or more substituents independently selected from (1-6C)alkyl, (1-4C)alkoxy, halogen, CF3, or (3-6C)cycloalkyl;
• m is 0, 1 or 2;
• hetAr2 is a 5-membered heteroaryl ring having 2-3 ring heteroatoms independently selected from N and S where at least one of said heteroatoms is N, wherein said ring is optionally substituted with one or more substituents independently selected from (1-6C)alkyl;
• hetAr3 is a bicyclic 5,6-fused heteroaryl ring having two ring nitrogen atoms;
• hetCyc1 is a 6-membered saturated heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O and optionally substituted with —C(═O)(1-6C alkyl) or —C(═O)O(1-6C alkyl);
• Ar1 is phenyl optionally substituted with one or more substituents independently selected from halogen, (1-6C)alkyl, CN, CF3, OH, (1-6C)alkoxy, —C(═O)OH, —C(═O)O(1-6C alkyl), —C(═O)NRaRb or benzyloxy;
• Ra and Rb are independently H or (1-6C)alkyl;
• n is 0, 1 or 2;
• R2 is H, F, Cl or CH3;
• R3 is H, F or Cl;
• R4 is H, CN, F, Cl, Br, —OMe, —OCF3, —CF3, —CH(OH)CH2OH or —C(═O)NH2;
• R5 is selected from:
• H,
• halogen,
• CN,
• OH,
• hetAr4,
• hetAr5,
• hetCyc2,
• hetCyc3(1-4Calkyl)-,
• hetCyc4(1-4C)alkoxy,
• hetCyc5(1-4C)alkoxy,
• (1-3C alkoxy)(1-4C)alkoxy,
• hydroxy(1-6C)alkoxy,
• dihydroxy(2-6C)alkoxy,
• (1-6C)alkoxy,
• [hydroxy(2-4C)alkyl)amino]-(1-4C)alkyl,
• [(1-4C alkoxy)(1-4C alkyl)amino](1-4C)alkyl,
• [di(1-4C alkyl)amino](1-4C)alkyl,
• (1-4C alkyl)C(═O)—,
• hydroxy(1-6C)alkyl,
• dihydroxy(2-6C)alkyl,
• [di(1-3C alkyl)amino](1-4C)alkoxy,
• N-(1-3C alkyl)pyridinone,
• hetAr6,
• hetCyc6C(═O)—,
• (hetCyc7)-O—,
• hetCyc8(1-4C)alkoxy,
• difluoroamino(1-4C)alkoxy,
• [(1-4C alkoxy)carbonylamide]difluoro(1-4C)alkoxy,
• (1-4C alkyl)C(═O)NH(2-4C)alkylthio-,
• (1-4Calkyl)OC(═O)—, or
• RcRdNC(═O)—;
• hetAr4 is a 5-membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O and S, wherein said ring is optionally substituted with one or more substituents independently selected from (1-6C)alkyl and [di(1-3C alkyl)amino]CH2—;
• hetAr5 is a 6-membered heteroaryl ring having 1-2 ring N atoms and optionally substituted with one or more substituents independently selected from (1-6C)alkyl;
• hetAr6 is a 9-membered partially unsaturated bicyclic heterocyclic ring having 3 ring N atoms and optionally substituted with one or more substituents independently selected from (1-6C)alkyl;
• hetCyc2 is a 5-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 ring heteroatoms selected from N and O, wherein said ring is optionally substituted with one or more substituents independently selected from (1-6C)alkyl, hydroxy(1-6C)alkyl, OH and oxo, provided said oxo is on a carbon atom;
• hetCyc3 is a 4-6 membered heterocyclic ring having 1-2 ring N atoms and optionally substituted with one or more substituents independently selected from (1-6C)alkyl, (1-6C)alkoxy and halogen;
• hetCyc4 is a 4-7 membered heterocycle having 1-2 ring heteroatoms independently selected from N, O and S, wherein one of said ring nitrogen atoms is optionally oxidized to N(0) and wherein said S ring atom is optionally oxidized to SO or SO2, wherein hetCyc4 is optionally substituted with one or more substituents independently selected from halogen, OH, (1-6C)alkyl, (1-4C alkoxy)(1-6C)alkyl, (1-4C)alkyl-OC(═O)— and (1-6C)alkoxy;
• hetCyc5 is a spiro heterocycle having 2 ring heteroatoms independently selected from N and O, wherein hetCyc5 is optionally substituted with a group selected from (1-6C)alkyl;
• hetCyc6 is a 6 membered heterocyclic ring having 1-2 ring N atoms and optionally substituted with one or more substituents independently selected from (1-6C)alkyl;
• hetCyc7 is a 4-6 membered heterocyclic ring having one or two ring N atoms and optionally substituted with one or more substituents independently selected from (1-6C)alkyl and OH;
• hetCyc8 is a bridged 8-membered heterocyclic ring having 2 ring atoms selected from N and O wherein at least one of said heteroatoms is N, wherein said ring is optionally substituted with (1-6C)alkyl;
• Rc is H or (1-4C)alkyl;
• Rd is (1-4C)alkyl, hetCyc10-, amino(1-4C)alkyl, or [di(1-4C alkyl)amino](1-4C)alkyl;
• hetCyc10 is a 5 membered heterocycle having a ring N atom and optionally substituted with one or more substituents independently selected from (1-6C)alkyl;
• and
• R6 is H or Cl.